Blogs
Why AI Is Becoming the Safest Operating Model for Community Banks
For decades, risk management in community and regional banking has centered on caution and control. New technology was often viewed through a defensive lens: something to be proven safe before being trusted at scale. That instinct has served the industry well.
Recent Posts
Why “Digital Transformation” Has Failed Most Community Banks
For more than a decade, digital transformation has been positioned as the answer to nearly every challenge facing community and regional banks. It promised leaner operations, faster decisions and better customer experiences in the face of growing competition from national banks and fintechs. Boards approved multi-year technology investments. Management teams launched modernization programs. Core systems were upgraded, data centers migrated, and cybersecurity capabilities expanded.
The Unexpected Edge: Why Smaller Institutions Can Outpace Larger Banks on AI Adoption
The banking landscape is shifting in ways most people haven't noticed. While headlines focus on major financial institutions and their billion-dollar technology budgets, a different competition is quietly developing. Community banks, operating with smaller technology budgets and leaner teams, are discovering advantages in the AI adoption race that larger institutions simply don't possess.
The New Definition of Scale in Banking: Why Operational Capability Now Matters More Than Asset Size
For decades, scale in banking was defined by size. Larger balance sheets delivered lower funding costs, broader product offerings, and greater resilience through diversification. Asset growth was the clearest path to competitive advantage, and mergers were the primary mechanism through which community and regional banks sought relevance in an increasingly consolidated industry.
The Hidden Risk of Delaying AI Adoption in Community Banking
For many U.S. community and regional banks, delaying AI adoption feels like a rational, even prudent choice. Regulatory scrutiny is intense, margins are under pressure, and leadership teams are understandably cautious about introducing new technology into mission-critical operations. In this context, “wait and watch” often appears safer than acting early.
The Billion-Dollar Waiting Game: How AI Is Transforming Clinical Trials
For all the breakthroughs that define modern medicine, pharmaceutical innovation still faces one stubborn obstacle: clinical trials. A promising molecule can demonstrate exceptional results in the laboratory, show encouraging preclinical safety data, and enter development with strong scientific rationale.
The $4 Billion Drug: Can AI Save Pharmaceutical Innovation?
The pharmaceutical industry finds itself at a paradoxical moment. Never before has science provided such a deep understanding of human biology, disease mechanisms, and genetic pathways. Advances in genomics, molecular biology, computational chemistry, and precision medicine have expanded the possibilities of therapeutic innovation at an unprecedented pace. Yet despite these scientific breakthroughs, the process of bringing a new drug to market remains extraordinarily expensive, time-consuming, and uncertain.
Pharma's Biggest AI Wins Aren't Happening in the Lab
When artificial intelligence is discussed in the pharmaceutical industry, the conversation almost always begins with drug discovery. The headlines focus on AI-generated molecules, protein structure prediction, and the possibility of dramatically reducing the time required to identify promising therapeutic candidates. These advances are undeniably significant and may reshape the future of pharmaceutical research.
Agentic AI in Banking: Hype, Reality, and the Five Places It Actually Delivers ROI
The Growing Disconnect Between AI Spend and Operational Impact Artificial intelligence has rapidly become one of the most discussed strategic themes in banking leadership forums.